secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-08-26T10:38:55+00:00
Accession:  0001935979-26-000072
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven licenses opakalim/Kv7 platform to SK Biopharmaceuticals for up to $795M
--------------------------------------------------------------------------------

- SK Biopharmaceuticals licenses Biohaven's Kv7 platform led by opakalim, a Phase 2/3 selective Kv7.2/7.3 activator for focal epilepsy.
- Biohaven receives $400M upfront ($350M at close, $50M in 2027) plus up to $150M development and regulatory milestones.
- Tiered royalties on U.S. opakalim net sales range from mid-teens to low twenties; mid-single-digit on ex-U.S. net sales.
- SKBP assumes up to $245M Knopp obligations: $185M on U.S./EMA approval of opakalim and up to $60M for future Kv7 programs.
- Closing subject to antitrust clearance (HSR); RISE3 topline results expected in 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/0001935979-26-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000072/bhvn-20260826.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer